Last mentioned: Mar 16, 2026
Abeona Therapeutics is set to report its fiscal year 2025 results, marking its transition from a clinical-stage developer to a commercial-stage biopharmaceutical entity. The primary focus for investors is the commercial trajectory of ZEVASKYN® for recessive dystrophic epidermolysis bullosa (RDEB) and the company's ability to manage complex cell therapy logistics.
This page surfaces every story mentioning Abeona Therapeutics across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Abeona Therapeutics was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |